Ultragenyx (RARE) Investors: Stifel Nicolaus Reconfirms Buy Rating, Sees $74.0/Share; Brinker Capital Has Raised Its Unitedhealth (UNH) Stake

February 21, 2018 - By Steve Bissell

Brinker Capital Inc increased Unitedhealth (UNH) stake by 26.72% reported in 2017Q3 SEC filing. Brinker Capital Inc acquired 7,778 shares as Unitedhealth (UNH)’s stock rose 9.50%. The Brinker Capital Inc holds 36,885 shares with $7.22 million value, up from 29,107 last quarter. Unitedhealth now has $219.94 billion valuation. The stock increased 0.28% or $0.63 during the last trading session, reaching $227.29. About 1.24 million shares traded. UnitedHealth Group Incorporated (NYSE:UNH) has risen 32.76% since February 21, 2017 and is uptrending. It has outperformed by 16.06% the S&P500.

Among 21 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 14 have Buy rating, 1 Sell and 6 Hold. Therefore 67% are positive. Ultragenyx Pharmaceutical Inc has $126 highest and $55.0 lowest target. $79.17’s average target is 70.22% above currents $46.51 stock price. Ultragenyx Pharmaceutical Inc had 58 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was maintained by Wedbush with “Outperform” on Thursday, March 23. Leerink Swann maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Wednesday, August 23 with “Buy” rating. SunTrust maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rating on Monday, July 13. SunTrust has “Buy” rating and $119 target. Morgan Stanley maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Friday, October 6 with “Equal-Weight” rating. The firm earned “Outperform” rating on Monday, January 22 by Evercore. The firm earned “Buy” rating on Monday, December 4 by Jefferies. The stock has “Buy” rating by Jefferies on Friday, October 23. On Wednesday, September 6 the stock rating was initiated by Barclays Capital with “Hold”. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Buy” rating by Cowen & Co on Thursday, June 29. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Neutral” rating by PiperJaffray on Thursday, March 23.

Investors sentiment decreased to 1.19 in 2017 Q3. Its down 0.65, from 1.84 in 2017Q2. It worsened, as 17 investors sold Ultragenyx Pharmaceutical Inc. shares while 40 reduced holdings. 15 funds opened positions while 53 raised stakes. 39.75 million shares or 1.85% less from 40.50 million shares in 2017Q2 were reported. Wells Fargo Company Mn has invested 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Ca holds 0.94% or 266,500 shares. Adage Cap Prtnrs Gp Lc accumulated 0.02% or 188,500 shares. Guggenheim Capital Ltd Co holds 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 68,994 shares. Goldman Sachs Group accumulated 618,811 shares. Capital Research Glob Invsts holds 4.09 million shares. State Bank Of America Corp De accumulated 69,773 shares. Intll Investors reported 2.90 million shares. D E Shaw Company Inc reported 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Victory Capital Mngmt Inc owns 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 443 shares. Eagle Asset Mngmt invested 0.16% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Clearbridge Ltd Limited Liability Company owns 1,097 shares. Moreover, Pacad Invest Limited has 0.06% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 5,300 shares. California Public Employees Retirement System holds 0% or 40,300 shares in its portfolio.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.18 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.

The stock decreased 3.47% or $1.67 during the last trading session, reaching $46.51. About 776,646 shares traded or 34.01% up from the average. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 6.49% since February 21, 2017 and is downtrending. It has underperformed by 23.19% the S&P500.

Investors sentiment decreased to 0.91 in Q3 2017. Its down 0.11, from 1.02 in 2017Q2. It turned negative, as 46 investors sold UNH shares while 524 reduced holdings. 112 funds opened positions while 408 raised stakes. 810.94 million shares or 0.66% less from 816.36 million shares in 2017Q2 were reported. 380,000 are held by Orbimed. D E Shaw Company Inc invested 0.01% in UnitedHealth Group Incorporated (NYSE:UNH). Wealthfront Inc holds 42,331 shares or 0.11% of its portfolio. Obermeyer Wood Investment Counsel Lllp owns 3.21% invested in UnitedHealth Group Incorporated (NYSE:UNH) for 189,245 shares. Carlson, a Minnesota-based fund reported 31,321 shares. Amalgamated Bancorporation accumulated 0.71% or 115,815 shares. Nicholas Partners LP accumulated 14,505 shares. Tradewinds Cap invested in 245 shares or 0.02% of the stock. Moreover, Univest Of Pennsylvania has 0.11% invested in UnitedHealth Group Incorporated (NYSE:UNH) for 1,351 shares. Gam Ag has 37,200 shares for 0.31% of their portfolio. Buffington Mohr Mcneal holds 2,135 shares or 0.18% of its portfolio. Financial Counselors Incorporated has 0.72% invested in UnitedHealth Group Incorporated (NYSE:UNH) for 75,560 shares. Trustmark Bancshares Department has 5,054 shares. Winslow Cap Mngmt Lc reported 3.01M shares or 3.17% of all its holdings. Eagle Mngmt Llc accumulated 16,667 shares.

Brinker Capital Inc decreased General Electric (NYSE:GE) stake by 38,138 shares to 261,307 valued at $6.34 million in 2017Q3. It also reduced Ishares Intl Select (IDV) stake by 54,834 shares and now owns 11,619 shares. Berry Global (NYSE:BERY) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Steve Bissell

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: